Jump to content

XYL-3001

Add links
From Wikipedia, the free encyclopedia
(Redirected from XYL3001)
XYL-3001
Clinical data
Other namesXYL3001; PSYLO-3001; PSYLO3001; Psylo-3001
Routes of
administration		Unspecified[1]
Drug classNon-hallucinogenic serotonin 5-HT2A receptor agonist

XYL-3001, formerly known as PSYLO-3001, is a non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders, generalized anxiety disorder, and social phobia (social anxiety disorder).[1][2][3] Its route of administration is unspecified.[1] The drug is being developed by Xylo Bio (previously Psylo).[1][2] As of January 2025, it is in the preclinical research stage of development.[1][2] XYL-3001's chemical structure does not yet appear to have been disclosed.[1]

References

[edit]
  1. ^ a b c d e f "PSYLO 3001". AdisInsight. 21 January 2025. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on PSYLO-300X with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ^ "Next generation neuroscience for transformative treatments". PSYLO. 28 October 2024. Retrieved 16 February 2025.



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=XYL-3001&oldid=1283681896"